Authors:
OKAMOTO H
NAGATOMO A
KUNITOH H
KUNIKANE H
WATANABE K
Citation: H. Okamoto et al., PREDICTION OF CARBOPLATIN CLEARANCE CALCULATED BY PATIENT CHARACTERISTICS OR 24-HOUR CREATININE CLEARANCE - A COMPARISON OF THE PERFORMANCEOF 3 FORMULAS, Cancer chemotherapy and pharmacology, 42(4), 1998, pp. 307-312
Authors:
NAGATOMO A
WATANABE K
KUNIKANE H
OKAMOTO H
KUNITOH H
Citation: A. Nagatomo et al., A RANDOMIZED CONTROLLED TRIAL OF SULFAMETHOXAZOLE TRIMETHOPRIM PLUS NORFLOXACIN VERSUS SULFAMETHOXAZOLE/TRIMETHOPRIM ALONE FOR THE PROPHYLAXIS OF BACTERIAL-INFECTION DURING CHEMOTHERAPY FOR LUNG-CANCER/, Lung cancer, 19(2), 1998, pp. 121-125
Authors:
OKAMOTO H
NAGATOMO A
KUNITOH H
KUNIKANE H
WATANABE K
Citation: H. Okamoto et al., A PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF A CARBOPLATIN AND IRINOTECAN REGIMEN COMBINED WITH RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN THE TREATMENT OF PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CARCINOMA, Cancer, 82(11), 1998, pp. 2166-2172
Authors:
RAMACHANDRAN C
KUNIKANE H
YOU W
KRISHAN A
Citation: C. Ramachandran et al., PHORBOL ESTER-INDUCED P-GLYCOPROTEIN PHOSPHORYLATION AND FUNCTIONALITY IN THE HTB-123 HUMAN BREAST-CANCER CELL-LINE, Biochemical pharmacology, 56(6), 1998, pp. 709-718
Authors:
KUNIKANE H
ZALUPSKI MM
RAMACHANDRAN C
KUKURUGA MA
LUCAS D
RYAN JR
KRISHAN A
Citation: H. Kunikane et al., FLOW CYTOMETRIC ANALYSIS OF P-GLYCOPROTEIN EXPRESSION AND DRUG EFFLUXIN HUMAN SOFT-TISSUE AND BONE SARCOMAS, Cytometry, 30(4), 1997, pp. 197-203
Authors:
INOMATA M
SAIJO N
KAWASHIMA K
KANEKO A
FUJIWARA Y
KUNIKANE H
TANAKA Y
Citation: M. Inomata et al., INDUCTION OF APOPTOSIS IN CULTURED RETINOBLASTOMA CELLS BY THE PROTEIN PHOSPHATASE INHIBITOR, OKADAIC ACID, Journal of cancer research and clinical oncology, 121(12), 1995, pp. 729-738
Authors:
OHMATSU H
EGUCHI K
SHINKAI T
TAMURA T
OHE Y
NISIO M
KUNIKANE H
ARIOKA H
KARATO A
NAKASHIMA H
SASAKI Y
TAJIMA K
TADA N
SAIJO N
Citation: H. Ohmatsu et al., A RANDOMIZED CROSS-OVER STUDY OF HIGH-DOSE METOCLOPRAMIDE PLUS DEXAMETHASONE VERSUS GRANISETRON PLUS DEXAMETHASONE IN PATIENTS RECEIVING CHEMOTHERAPY WITH HIGH-DOSE CISPLATIN, Japanese journal of cancer research, 85(11), 1994, pp. 1151-1158
Authors:
TAMURA T
SASAKI Y
EGUCHI K
SHINKAI T
OHE Y
NISHIO M
KUNIKANE H
ARIOKA H
KARATO A
OMATSU H
NAKASHIMA H
SAIJO N
Citation: T. Tamura et al., PHASE-I AND PHARMACOKINETIC STUDY OF PACLITAXEL BY 24-HOUR INTRAVENOUS-INFUSION, Japanese journal of cancer research, 85(10), 1994, pp. 1057-1062
Authors:
KUBOTA N
NISHIO K
TAKEDA Y
OHMORI T
FUNAYAMA Y
OGASAWARA H
OHIRA T
KUNIKANE H
TERASHIMA Y
SAIJO N
Citation: N. Kubota et al., CHARACTERIZATION OF AN ETOPOSIDE-RESISTANT HUMAN OVARIAN-CANCER CELL-LINE, Cancer chemotherapy and pharmacology, 34(3), 1994, pp. 183-190
Authors:
OHIRA T
OHE Y
HEIKE Y
PODACK ER
OLSEN KJ
NISHIO F
NISHIO M
MIYAHARA Y
FUNAYAMA Y
OGASAWARA H
ARIOKA H
KUNIKANE H
FUKUDA M
KATO H
SAIJO N
Citation: T. Ohira et al., IN-VITRO AND IN-VIVO GROWTH OF B16F10 MELANOMA-CELLS TRANSFECTED WITHINTERLEUKIN-4 CDNA AND GENE-THERAPY WITH THE TRANSFECTANT, Journal of cancer research and clinical oncology, 120(11), 1994, pp. 631-635
Authors:
KUNIKANE H
ABE S
YAMAGUCHI E
APARICIO JMR
WAKISAKA A
YOSHIKI T
KAWAKAMI Y
Citation: H. Kunikane et al., ANALYSIS OF RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM FOR THE HLA-DR GENE IN JAPANESE PATIENTS WITH SARCOIDOSIS, Thorax, 49(6), 1994, pp. 573-576
Authors:
SHINKAI T
ARIOKA H
KUNIKANE H
EGUCHI K
SASAKI Y
TAMURA T
OHE Y
OSHITA F
NISHIO M
KARATO A
OKAMOTO H
NAKASHIMA H
OHMATSU H
SHIRAISHI J
NOMURA N
SAIJO N
Citation: T. Shinkai et al., PHASE-I CLINICAL-TRIAL OF IRINOTECAN (CPT-11), PIPERIDINO)-1-PIPERIDINO]CARBONYLOXY-CAMPTOTHECIN, AND CISPLATIN IN COMBINATION WITH FIXED-DOSE OF VINDESINE IN ADVANCED NONSMALL CELL LUNG-CANCER, Cancer research, 54(10), 1994, pp. 2636-2642
Authors:
KARATO A
SASAKI Y
SHINKAI T
EGUCHI K
TAMURA T
OHE Y
OSHITA F
NISHIO M
KUNIKANE H
ARIOKA H
OHMATSU H
NAKASHIMA H
SHIRAISHI J
SAIJO N
Citation: A. Karato et al., PHASE-I STUDY OF CPT-11 AND ETOPOSIDE IN PATIENTS WITH REFRACTORY SOLID TUMORS, Journal of clinical oncology, 11(10), 1993, pp. 2030-2035